Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andrew R Blight

Showing results (21-30 of 36) with videos related to

Pageof 4
Sort By:
Multiple Sclerosis (Houndmills, Basingstoke, England)|January 14, 2015
Long-term safety and efficacy of dalfampridine for walking impairment in patients with multiple sclerosis: Results of open-label extensions of two Phase 3 clinical trialsAndrew D Goodman, Francois Bethoux, Theodore R Brown, et al.
Lancet (London, England)|March 3, 2009
Sustained-release oral fampridine in multiple sclerosis: a randomised, double-blind, controlled trialAndrew D Goodman, Theodore R Brown, Lauren B Krupp, et al.
Annals of Neurology|October 27, 2010
A phase 3 trial of extended release oral dalfampridine in multiple sclerosisAndrew D Goodman, Theodore R Brown, Keith R Edwards, et al.
Clinical Therapeutics|January 30, 2017
Safety, Tolerability, and Sensorimotor Effects of Extended-release Dalfampridine in Adults With Cerebral Palsy: A Pilot StudyFrancois Bethoux, Ali Fatemi, Eileen Fowler, et al.
Topics in Spinal Cord Injury Rehabilitation|December 15, 2012
Outcome Measures for Acute/Subacute Cervical Sensorimotor Complete (AIS-A) Spinal Cord Injury During a Phase 2 Clinical TrialJohn D Steeves, Daniel P Lammertse, John L K Kramer, et al.
Clinical Neuropharmacology|August 5, 2003
Pharmacokinetic studies of single and multiple oral doses of fampridine-SR (sustained-release 4-aminopyridine) in patients with chronic spinal cord injuryKeith C Hayes, Patrick J Potter, Robert R Hansebout, et al.
Stroke|May 9, 2013
Dalfampridine improves sensorimotor function in rats with chronic deficits after middle cerebral artery occlusionJennifer F Iaci, Tom J Parry, Zhihong Huang, et al.
International Journal of MS Care|June 9, 2015
Evaluation of Dalfampridine Extended Release 5 and 10 mg in Multiple Sclerosis: A Randomized Controlled TrialRobert Yapundich, Angela Applebee, Francois Bethoux, et al.
CNS Drugs|December 12, 2018
Assessment of Clinically Meaningful Improvements in Self-Reported Walking Ability in Participants with Multiple Sclerosis: Results from the Randomized, Double-Blind, Phase III ENHANCE Trial of Prolonged-Release FampridineJeremy Hobart, Tjalf Ziemssen, Peter Feys, et al.
Spinal Cord|April 10, 2019
The challenge of recruitment for neurotherapeutic clinical trials in spinal cord injuryAndrew R Blight, Jane Hsieh, Armin Curt, et al.
Pageof 4

Showing results (21-30 of 36) with videos related to

Sort By:
Pageof 4
Multiple Sclerosis (Houndmills, Basingstoke, England)|January 14, 2015
Long-term safety and efficacy of dalfampridine for walking impairment in patients with multiple sclerosis: Results of open-label extensions of two Phase 3 clinical trialsAndrew D Goodman, Francois Bethoux, Theodore R Brown, et al.
Lancet (London, England)|March 3, 2009
Sustained-release oral fampridine in multiple sclerosis: a randomised, double-blind, controlled trialAndrew D Goodman, Theodore R Brown, Lauren B Krupp, et al.
Annals of Neurology|October 27, 2010
A phase 3 trial of extended release oral dalfampridine in multiple sclerosisAndrew D Goodman, Theodore R Brown, Keith R Edwards, et al.
Clinical Therapeutics|January 30, 2017
Safety, Tolerability, and Sensorimotor Effects of Extended-release Dalfampridine in Adults With Cerebral Palsy: A Pilot StudyFrancois Bethoux, Ali Fatemi, Eileen Fowler, et al.
Topics in Spinal Cord Injury Rehabilitation|December 15, 2012
Outcome Measures for Acute/Subacute Cervical Sensorimotor Complete (AIS-A) Spinal Cord Injury During a Phase 2 Clinical TrialJohn D Steeves, Daniel P Lammertse, John L K Kramer, et al.
Clinical Neuropharmacology|August 5, 2003
Pharmacokinetic studies of single and multiple oral doses of fampridine-SR (sustained-release 4-aminopyridine) in patients with chronic spinal cord injuryKeith C Hayes, Patrick J Potter, Robert R Hansebout, et al.
Stroke|May 9, 2013
Dalfampridine improves sensorimotor function in rats with chronic deficits after middle cerebral artery occlusionJennifer F Iaci, Tom J Parry, Zhihong Huang, et al.
International Journal of MS Care|June 9, 2015
Evaluation of Dalfampridine Extended Release 5 and 10 mg in Multiple Sclerosis: A Randomized Controlled TrialRobert Yapundich, Angela Applebee, Francois Bethoux, et al.
CNS Drugs|December 12, 2018
Assessment of Clinically Meaningful Improvements in Self-Reported Walking Ability in Participants with Multiple Sclerosis: Results from the Randomized, Double-Blind, Phase III ENHANCE Trial of Prolonged-Release FampridineJeremy Hobart, Tjalf Ziemssen, Peter Feys, et al.
Spinal Cord|April 10, 2019
The challenge of recruitment for neurotherapeutic clinical trials in spinal cord injuryAndrew R Blight, Jane Hsieh, Armin Curt, et al.
Pageof 4